4 biotechs to watch in 2024

We’re only halfway through February, and there’s already optimism that 2024 will bring an upturn for biotech, thanks to buzzy upcoming approval dates and an early crop of successful IPOs that gave the sector its best start since 2021, according to Bloomberg.

The industry is also coming off a year of historic firsts — from a vaccine for RSV and a drug that could slow Alzheimer’s disease, to the first CRISPR-based drug.

Drawing on forecasting reports from Evaluate and Citeline, company news and financial analysis, we’ve compiled a list of four biotechs to watch in 2024.